Proteros Appoints Dr. Torsten Hoffmann as Chief Scientific Officer
News Jun 30, 2015
Proteros biostructures GmbH has announced the appointment of Dr. Torsten Hoffmann as Chief Scientific Officer (CSO), effective from July 1st, 2015. In this newly created role at Proteros, he will support the further growth of the Proteros Discovery business and act as Member of the Management Board.
Dr. Hoffmann has more than 18 years of international scientific and research management experience. Before joining Proteros, Dr. Hoffmann was Chief Scientific Officer at Denmark-based Zealand Pharma A/S and Head of Discovery Chemistry at Roche in Basel.
He is inventor of an anti-emetic medicine which received FDA approval as Akynzeo® in 2014. Under his leadership at Roche more than 20 new chemical entities entered into clinical trials and 52 new chemical lead series were created.
From 2005 to 2013, Dr. Hoffmann assumed increasing responsibility at Roche, including Head of Discovery Chemistry with responsibility for 170 employees at the company's headquarters in Basel, Switzerland. At Zealand Pharma he was responsible for all R&D activities of the company and establishing a broad R&D pipeline.
The work under leadership of Dr. Hoffmann is documented in over 280 peer reviewed publications and 540 patent applications. He holds a Ph.D. in Chemistry from the Eidgenössische Technische Hochschule (ETH) in Zurich, Switzerland with Prof. Dieter Seebach, and did postdoctoral research with Prof. Richard Lerner at The Scripps Research Institute in La Jolla, CA, US.
"I am delighted to welcome Dr. Torsten Hoffmann to the team of Proteros. His track record in drug discovery and outstanding management expertise in both pharma and biotech companies will support us in achieving our further growth plans over the coming years," commented Dr. Torsten Neuefeind, CEO of Proteros. "Along with this and complementary to Dr. Peter Reinemer's function as COO, Dr. Hoffmann will be a great addition to our team."
Dr. Torsten Hoffmann added: "I am very impressed by the capabilities and the attractive business model of Proteros. The unique expertise in working on the most challenging targets and a prosperous business, working with almost all the big pharma companies, gives Proteros an outstanding position. It will be a pleasure to work with this highly motivated team."
Sartorius Stedim Biotech and Siemens Sign Automation AgreementNews
Siemens becomes a preferred supplier for automation solutions. Product portfolio of Sartorius Stedim Biotech to feature a globally standardized automation platform in the future.READ MORE
Structure of Amino Acid Transporter Involved in Cancer RevealedNews
The human glutamine transporter ASCT2 is upregulated in several forms of cancer. It is also the docking platform for a wide range of pathogenic retroviruses. A team of University of Groningen scientists have used cryo-electron microscopy to elucidate the structure of the protein, which may generate leads for drug development.READ MORE
Comments | 0 ADD COMMENT
10th Annual Congress on Drug Formulation & Analytical Techniques
Sep 03 - Sep 04, 2018